Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Travis WD, Asamura H, Bankier AA, Beasley MB, Detterbeck F, Flieder DB, et al. The IASLC Lung Cancer Staging Project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2016;11(8):1204–23.

Article  PubMed  Google Scholar 

Ou SH, Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol. 2009;4(10):1202–11.

Article  PubMed  Google Scholar 

Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol. 2021;12(4):217–37.

Article  PubMed  PubMed Central  Google Scholar 

Lung J, Hung MS, Lin YC, Lee KF, Jiang YY, Huang SL, et al. MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population. PLoS ONE. 2019;14(8): e0220670.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat Rev Cancer. 2018;18(6):341–58.

Article  CAS  PubMed  Google Scholar 

Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019;133:96–102.

Article  PubMed  Google Scholar 

Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018;29(10):2085–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chapman AM, Sun KY, Ruestow P, Cowan DM, Madl AK. Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers. Lung Cancer. 2016;102:122–34.

Article  PubMed  Google Scholar 

National Comprehensive Cancer Network. NCCN guidelines 2023. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450. Accessed 18 Feb 2024.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl. 4):192–237.

Article  Google Scholar 

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hur JY, Ku BM, Shim JH, Jung HA, Sun JM, Lee SH, et al. Characteristics and clinical outcomes of non-small cell lung cancer patients in Korea with MET exon 14 skipping. In Vivo. 2020;34(3):1399–406.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383(10):931–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Medicines and Healthcare products Regulatory Agency (MHRA). Summary of product characteristics: TEPMETKO 2021. Available from: https://mhraproducts4853.blob.core.windows.net/docs/d9ea0989d5988892d2ff6ac6ec36b73871f0e4db. Accessed 18 Feb 2024.

US Food and Drug Administration. Highlights of prescribing information for Tepmetko® (tepotinib) tablets. 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf. Accessed 18 Feb 2024.

National Institute of Health and Care Excellence (NICE). TA789: tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations 2022. Available from: https://www.nice.org.uk/guidance/ta789. Accessed 18 Feb 2024.

Scottish Medicines Consortium (SMC). SMC2535: tepotinib (Tepmetko) 2023. Available from: https://www.scottishmedicines.org.uk/medicines-advice/tepotinib-tepmetko-resub-smc2535/. Accessed 18 Feb 2024.

Mazieres J, Paik PK, Garassino MC, Le X, Sakai H, Veillon R, et al. Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung cancer: long-term follow-up of the VISION phase 2 nonrandomized clinical trial. JAMA Oncol. 2023;9(9):1260–6.

Article  PubMed  PubMed Central  Google Scholar 

National Institute of Health and Care Excellence (NICE). TA347: nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer 2015. Available from: https://www.nice.org.uk/guidance/ta347. Accessed 18 Feb 2024. Accessed 18 Feb 2024.

National Institute of Health and Care Excellence (NICE). TA402: pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin 2016. Available from: https://www.nice.org.uk/guidance/ta402. Accessed 18 Feb 2024.

National Institute of Health and Care Excellence (NICE). TA428: pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy 2017. Available from: https://www.nice.org.uk/guidance/ta428. Accessed 18 Feb 2024.

National Institute of Health and Care Excellence (NICE). TA520: atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy 2018. Available from: https://www.nice.org.uk/guidance/ta520. Accessed 18 Feb 2024.

National Institute of Health and Care Excellence (NICE). TA531: pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer 2018. Available from: https://www.nice.org.uk/guidance/ta531. Accessed 18 Feb 2024.

National Institute of Health and Care Excellence (NICE). TA584: atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer 2019. Available from: https://www.nice.org.uk/guidance/ta584. Accessed 18 Feb 2024.

National Institute of Health and Care Excellence (NICE). TA600: pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer 2019. Available from: https://www.nice.org.uk/guidance/ta600. Accessed 18 Feb 2024.

National Institute of Health and Care Excellence (NICE). TA655: nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy 2020. Available from: https://www.nice.org.uk/guidance/ta655. Accessed 18 Feb 2024.

National Institute of Health and Care Excellence (NICE). TA683: pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer 2021. Available from: https://www.nice.org.uk/guidance/ta683. Accessed 18 Feb 2024.

National Institute of Health and Care Excellence (NICE). NICE health technology evaluations: the manual 2022. Available from: https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation. Accessed 18 Feb 2024.

National Institute of Health and Care Excellence (NICE). NG122: lung cancer: diagnosis and management 2023. Available from: https://www.nice.org.uk/guidance/ng122. Accessed 18 Feb 2024.

Rodríguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32(7):881–95.

Article  PubMed  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol. 2021;39(21):2339–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vioix H, Hatswell A, McLean T, Day C, Batteson R, Hook E, et al. CO94 Tepotinib compared with chemoimmunotherapy in first-line non-small cell lung cancer (NSCLC): matching adjusted indirect comparison (MAIC) of VISION in MET exon 14 (METex14) skipping NSCLC and KEYNOTE-189 in Wild-type NSCLC. Value Health. 2022;25(12):S36.

Article  Google Scholar 

Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–55.

Article  CAS  PubMed  Google Scholar 

Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–73.

Article  CAS  PubMed  Google Scholar 

Batteson R, Hook E, Vioix H, Hatswell A. RWD51 demonstrating internal and external validity in real-world datasets: a case study in MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC). Value Health. 2022;25(12):S458.

Article  Google Scholar 

Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.

Article  PubMed  PubMed Central  Google Scholar 

Latimer N. NICE DSU Technical Support Document 14: survival analysis for economic evaluations alongside clinical trials: extrapolations with patient-level data 2013. Available from: http://nicedsu.org.uk/wp-content/uploads/2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf. Accessed 18 Feb 2024.

van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–15.

Article  PubMed  Google Scholar 

National Institute of Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. Available from: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed 18 Feb 2024.

Yang M, Vioix H, Hook ES, Hatswell AJ, Batteson RL, Gaumond BR, et al. Health utility analysis of tepotinib in patients with non-small cell lung cancer harboring MET exon 14 skipping. Value Health. 2023;26(8):1155–63.

Article  PubMed  Google Scholar 

Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38(14):1505–17.

Article  CAS  PubMed  Google Scholar 

Guisier F, Dubos-Arvis C, Viñas F, Doubre H, Ricordel C, Ropert S, et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01–2018. J Thorac Oncol. 2020;15(4):628–36.

Article  CAS  PubMed  Google Scholar 

Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30.

Article  CAS  PubMed  Google Scholar 

Herbst RS, Garon EB, Kim DW, Cho BC, Gervais R, Perez-Gracia JL, et al. Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC. J Thorac Oncol. 2021;16(10):1718–32.

Article  CAS  PubMed  Google Scholar 

Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro CJ, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cramer-van der Welle CM, Verschueren MV, Tonn M, Peters BJM, Schramel F, Klungel OH, et al. Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cance